@article{88944c1a1f424a438e79b257074a0fcd,
title = "Big Data From Small Devices: The Future of Smartphones in Oncology",
abstract = "Technological advancements in the capabilities of modern smartphones offer tremendous potential to generate big data from small devices that could influence oncologists{\textquoteright} decision-making. Here we describe the value of patient-generated health data (PGHD) that can be captured using mobile devices. We comment on the current use of smartphones in oncology clinical research and describe how smartphones will bring big data into the oncology clinic by enabling continuous patient monitoring, information sharing, and personalized clinical decision making in cancer care. Lastly, we describe practical considerations about how we can access and store PGHD in the future, describing how to harness the clinical value of PGHD and comment on the emerging applications for digital biomarkers captured by smartphones.",
author = "Purswani, {Juhi M.} and Dicker, {Adam P.} and Champ, {Colin E.} and Matt Cantor and N. Ohri",
note = "Funding Information: Financial and Conflicts of Interests Disclosure: Dr. Dicker is supported by a Challenge grant from the Prostate Cancer Foundation . Research reported in this publication utilized the resources at Sidney Kimmel Cancer Center at Jefferson Health and was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA056036 . Dr. Ohri receives consulting fees from Merck and AstraZeneca and research support from Merck. Neither Merck nor AstraZeneca provided input into manuscript preparation or any aspects of this work. There are no relevant affiliations, financial disclosures, conflicts of interest, and/or acknowledgements for all the other authors. Funding Information: Financial and Conflicts of Interests Disclosure: Dr. Dicker is supported by a Challenge grant from the Prostate Cancer Foundation. Research reported in this publication utilized the resources at Sidney Kimmel Cancer Center at Jefferson Health and was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA056036. Dr. Ohri receives consulting fees from Merck and AstraZeneca and research support from Merck. Neither Merck nor AstraZeneca provided input into manuscript preparation or any aspects of this work. There are no relevant affiliations, financial disclosures, conflicts of interest, and/or acknowledgements for all the other authors. Financial and Conflicts of Interests Disclosure: Dr. Dicker is supported by a Challenge grant from the Prostate Cancer Foundation. Research reported in this publication utilized the resources at Sidney Kimmel Cancer Center at Jefferson Health and was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA056036. Dr. Ohri receives consulting fees from Merck and AstraZeneca and research support from Merck. Neither Merck nor AstraZeneca provided input into manuscript preparation or any aspects of this work. There are no relevant affiliations, financial disclosures, conflicts of interest, and/or acknowledgements for all the other authors. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = oct,
doi = "10.1016/j.semradonc.2019.05.008",
language = "English (US)",
volume = "29",
pages = "338--347",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "4",
}
